HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
INFU
InfuSystem Holdings, Inc.
INFU's fundamentals are strong: it turned 17% of its revenue into free cash flow and earnings per share grew 63%. At 34x earnings, it's trading below its usual 50x. Analysts expect strong earnings growth.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
INFU Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Strong |
INFU's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
INFU PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 25x | $14.79 | — |
| Cheap | 28x | $12.19 | -18% |
| Current | 34x | $14.79 | — |
| Fair | 50x | $21.97 | +49% |
| Expensive | 333x | $146 | +890% |
Historical ranges are pointers, not guarantees.
INFU's PE is in its cheap range at 34x. If earnings grow as analysts expect, today's price would be 25x next year's earnings.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
INFU Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect INFU's earnings to grow and its profitability to improve, with its revenue holding steady.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
INFU Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.59 | +34% |
| Q3 2026 | $0.44 | +63% |
| Q2 2026 | $0.40 | +67% |
| Q1 2026 | $0.37 | +147% |
| Q4 2025 | $0.31 | +182% |
| Q3 2025 | $0.27 | +286% |
| Q2 2025 | $0.24 | +1100% |
| Q1 2025 | $0.15 | +1400% |
| Q4 2024 | $0.11 | +175% |
INFU has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over INFU on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
INFU Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $37.6M | +3% |
| Q2 2026 | $36.9M | +2.6% |
| Q1 2026 | $33.7M | -3% |
| Q4 2025 | $36.2M | +7% |
| Q3 2025 | $36.5M | +3.3% |
| Q2 2025 | $36M | +6.8% |
| Q1 2025 | $34.7M | +8.5% |
| Q4 2024 | $33.8M | +6.5% |
INFU's revenue grew through 2024 and has held roughly level since: $38M last quarter, up 3% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 13% | +2.2 points |
| Q2 2026 | 11% | +0.8 points |
| Q1 2026 | 4.7% | +2.9 points |
| Q4 2025 | 10% | +2.5 points |
| Q3 2025 | 10% | +1.2 points |
| Q2 2025 | 10% | +5 points |
| Q1 2025 | 1.8% | +4.4 points |
| Q4 2024 | 7.7% | +3.8 points |
INFU has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over INFU on cash flow, with more consistent year-over-year improvement.
INFU Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $10.3M | +22% |
| Q2 2026 | $6.7M | -1.6% |
| Q1 2026 | $813K | -51% |
| Q4 2025 | $7M | -5.5% |
| Q3 2025 | $8.4M | -14% |
| Q2 2025 | $6.8M | +244% |
| Q1 2025 | $1.6M | +746% |
| Q4 2024 | $7.4M | +74% |
INFU generated $25M in free cash flow over the past year, up 2.1% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over INFU on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
INFU Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.7% | +152K shares |
| 1 year | +0.6% | +126K shares |
| 3 years | -3% | -647K shares |
| 5 years | +2.4% | +494K shares |
| Available history | +1.1% | +233K shares |
INFU has 21M diluted shares, up 0.6% from a year ago, despite $6M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $605,000 |
| Q2 2026 | $3.5M |
| Q1 2026 | $809,000 |
| Q4 2025 | $1.3M |
| Q3 2025 | $2.2M |
| Q2 2025 | $3.5M |
| Q1 2025 | $2.9M |
| Q4 2024 | $199,000 |
INFU spent $6M buying back its own shares over the past year, down 28% from the year before.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
INFU Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.4x | Very low |
| Q2 2026 | 0.7x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.7x | Very low |
| Q3 2025 | 0.8x | Very low |
| Q2 2025 | 1.1x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.2x | Healthy |
INFU's net debt is less than a year of its operating earnings (EBITDA).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
INFU Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 73.2 | Overbought |
| Stochastic | 84.8 | Overbought |
INFU's weekly RSI is 73 (overbought) and its Stochastic is 85 (overbought).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
INFU PE vs Healthcare Sector
| Metric | INFU | Sector median | Relative |
|---|---|---|---|
| PE | 34x | 26x | 30% above |
| PE % | 31 | 29 | 2 pts above |
INFU is trading at 34x earnings, a 30% premium to the Healthcare sector's median of 26x.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
INFU Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $13.7 | 8.3% above |
| 20 week MA | $12.1 | 22% above |
| 50 week MA | $10.3 | 44% above |
| 100 week MA | $8.93 | 66% above |
| 200 week MA | $8.82 | 68% above |
INFU has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
INFU Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $8.22 | $19.0 | +131% |
| 2021 | $19.0 | $16.9 | -11% |
| 2022 | $16.9 | $8.50 | -50% |
| 2023 | $8.50 | $10.5 | +24% |
| 2024 | $10.5 | $8.14 | -23% |
| 2025 | $8.14 | $8.96 | +10% |
| 2026 YTD | $8.96 | $14.8 | +65% |
INFU has the edge over HIMS on returns for 2026, with the stronger performance.